StoneX Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

StoneX Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,876	Closed	-$244K	–	593
2021 Q3	$244K	Sell	1,876 -9	-0.5%	-$1.36K	0.04%	416
2021 Q2	$335K	Buy	1,885 +55	+3%	+$9.53K	0.05%	328
2021 Q1	$301K	Sell	1,830 -24	-1%	-$3.95K	0.05%	299
2020 Q4	$306K	Hold	1,854	–	–	0.07%	262
2020 Q3	$264K	Hold	1,854	–	–	0.09%	250
2020 Q2	$205K	Buy	+1,854	New	+$205K	0.08%	271
2020 Q1	–	Sell	-1,898	Closed	-$283K	–	288
2019 Q4	$283K	Hold	1,898	–	–	0.12%	221
2019 Q3	$243K	Sell	1,898 -36	-2%	-$4.83K	0.15%	201
2019 Q2	$276K	Buy	1,934 +2	+0.1%	+$269	0.18%	179
2019 Q1	$276K	Buy	+1,932	New	+$252K	0.21%	174
2018 Q4	–	Sell	-1,962	Closed	-$330K	–	224
2018 Q3	$330K	Hold	1,962	–	–	0.25%	148
2018 Q2	$338K	Hold	1,962	–	–	0.29%	121
2018 Q1	$296K	Buy	+1,962	New	+$288K	0.28%	141
2017 Q4	–	Sell	-1,454	Closed	-$213K	–	205
2017 Q3	$213K	Sell	1,454 -27	-2%	-$4.08K	0.27%	152
2017 Q2	$230K	Buy	+1,481	New	+$226K	0.07%	335

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

StoneX Group's JAZZ Position: Q4 2021 in Review

StoneX Group sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2021, closing a stake of 1,876 shares — an estimated $244K sold.

StoneX Group first reported a position in JAZZ in Q2 2017 and held it in 15 quarters. The position peaked at $338K in Q2 2018. 454 funds tracked by Wall St. Rank hold JAZZ as of Q4 2021.

StoneX Group reported no remaining Jazz Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
StoneX Group sold 1,876 Jazz Pharmaceuticals shares in Q4 2021, an estimated $244K.
StoneX Group first reported a position in Jazz Pharmaceuticals in Q2 2017 and held it in 15 quarters.
StoneX Group's Jazz Pharmaceuticals position peaked at $338K in Q2 2018.
454 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2021.

Based on StoneX Group's 13F filing for Q4 2021, filed 10 Feb 2022.